诺和诺德与礼来主导的减肥药市场正快速转向口服疗法,英国和欧洲已批准诺和诺德的Wegovy口服版,礼来的orforglipron则于4月获美国批准。 https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-bulk-up-with-bets-weight-loss-treatments-2026-09-21/

来源:路透社
诺和诺德与礼来主导的减肥药市场正快速转向口服疗法,英国和欧洲已批准诺和诺德的Wegovy口服版,礼来的orforglipron则于4月获美国批准。 https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-bulk-up-with-bets-weight-loss-treatments-2026-09-21/

来源:路透社